Drug intelligence / Profile preview

bortezomib + thalidomide + rituximab

Development stage: Unknown
Lead developer: Takeda
Modality: Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous (bortezomib), Oral (thalidomide), Intravenous (rituximab)

Overview

This combination involves **bortezomib**, a proteasome inhibitor; **thalidomide**, an immunomodulatory drug; and **rituximab**, a monoclonal antibody targeting CD20. It is used in the treatment of certain cancers, including lymphomas and multiple myeloma. The mechanism of action involves inhibiting proteasome function, modulating immune responses, and targeting B cells.

Other names: 硼替佐米 + 沙利度胺 + 利妥昔单抗

Targets

CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)PSMB5 (Proteasome subunit beta Type-5)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on bortezomib + thalidomide + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bortezomib + thalidomide + rituximab.

Explore the full profile